|
1.
|
National Asthma Council Australia. Asthma Management Handbook 2006. Melbourne: National Asthma Council Australia, 2006.
|
|
2.
|
Henderson J, Knox S, Pan Y, Britt H. Changes in asthma management in Australian general practice.
Prim Care Respir J 2004; 13: 138-43.
|
|
3.
|
Robertson CF, Price D, Henry R et al. Short-course montelukast for intermittent asthma in children: a randomized controlled trial.
Am J Respir Crit Care Med 2007; 175: 323-9.
|
|
4.
|
Fitzgerald DA, Mellis CM. Leukotriene receptor antagonists in virus-induced wheezing: evidence to date.
Treat Respir Med 2006; 5: 407-17.
|
|
5.
|
Volovitz B, Duenas-Meza E, Chmielewska-Szewczyk DA et al. Comparison of oral montelukast and inhaled cromolyn with respect to preference, satisfaction, and adherence: a multi-center, randomized, open-label, crossover study in children with mild to moderate persistent asthma.
Curr Ther Res Clin Exp 2000; 61: 490-506.
|
|
6.
|
Vuillermin P, South M, Robertson C. Parent-initiated oral corticosteroid therapy for intermittent wheezing illnesses in children.
Cochrane Database Syst Rev 2006; 3.
|
|
7.
|
Oommen A, Lambert PC, Grigg J. Effi cacy of a short course of parent-initiated oral prednisolone for viral wheeze in children aged 1-5 years: randomised controlled trial.
Lancet 2003; 362: 1433-8.
|
|
8.
|
McKean M, Ducharme F. Inhaled steroids for episodic viral wheeze of childhood.
Cochrane Database Syst Rev 2000; 1.
|
|
9.
|
Merck Sharp & Dohme (MSD). Singulair (Montelukast sodium) Australian Approved Product Information. Melbourne: MSD, 2007.
|
|
10.
|
Pajaron-Fernandez M, Garcia-Rubia S, Sanchez-Solis M, Garcia- Marcos L. Montelukast administered in the morning or evening to prevent exercise-induced bronchoconstriction in children.
Pediatr Pulmonol 2006; 41: 222-7.
|
|
11.
|
Peroni DG, Piacentini GL, Ress M et al. Time efficacy of a single dose of montelukast on exercise-induced asthma in children.
Pediatr Allergy Immunol 2002; 13: 434-7.
|
|
12.
|
de Benedictis FM, del Giudice MM, Forenza N et al. Lack of tolerance to the protective effect of montelukast in exercise-induced bronchoconstriction in children.
Eur Respir J 2006; 28: 291-5.
|
|
13.
|
Knorr B, Franchi LM, Bisgaard H et al. Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years.
Pediatrics 2001; 108: E48.
|
|
14.
|
Knorr B, Matz J, Bernstein JA et al. Montelukast for chronic asthma in 6- to 14-year-old children: a randomized, double-blind trial. Pediatric Montelukast Study Group.
JAMA 1998; 279: 1181-6.
|
|
15.
|
Becker AB, Kuznetsova O, Vermeulen J et al. Linear growth in prepubertal asthmatic children treated with montelukast, beclomethasone, or placebo: a 56-week randomized double-blind study. Pediatric Montelukast Linear Growth Study Group.
Ann Allergy Asthma Immunol 2006; 96: 800-7.
|
|
16.
|
Garcia Garcia ML, Wahn U, Gilles L et al. Montelukast, compared with fl uticasone, for control of asthma among 6- to 14-year-old patients with mild asthma: The MOSAIC Study.
Pediatrics 2005; 116: 360-9.
|
|
17.
|
Becker A, Swern A, Tozzi CA et al. Montelukast in asthmatic patients 6 years-14 years old with an FEV1 > 75%. Curr Med Res Opin 2004; 20: 1651-9.
|
|
18.
|
Meyer KA, Arduino JM, Santanello NC et al. Response to montelukast among subgroups of children aged 2 to 14 years with asthma.
J Allergy Clin Immunol 2003; 111: 757-62.
|
|
19.
|
Luskin AT, Bernstein A. ‘Real-world' effectiveness of daily controller medicine in children with mild persistent asthma.
Ann Allergy Asthma Immunol 2003; 90: 543-9.
|
|
20.
|
Sorkness CA, Lemanske RF, Mauger DT et al. Long-term comparison of 3 controller regimens for mild-moderate persistent childhood asthma: The Pediatric Asthma Controller Trial.
J Allergy Clin Immunol 2007; 119: 64-72.
|
|
21.
|
Zeiger RS, Szefl er SJ, Phillips BR et al. Response profi les to fl uticasone and montelukast in mild-to-moderate persistent childhood asthma.
J Allergy Clin Immunol 2006; 117: 45-52.
|
|
22.
|
Ostrom NK, Decotiis BA, Lincourt WR et al. Comparative effi cacy and safety of low-dose fl uticasone propionate and montelukast in children with persistent asthma.
J Pediatr 2005; 147: 213-20.
|
|
23.
|
Jat GC, Mathew JL, Singh M. Treatment with 400 microg of inhaled budesonide vs 200 microg of inhaled budesonide and oral montelukast in children with moderate persistent asthma: randomized controlled trial.
Ann Allergy Asthma Immunol 2006; 97: 397-401.
|
|
24.
|
Szefl er SJ, Phillips BR, Martinez FD et al. Characterization of withinsubject responses to fluticasone and montelukast in childhood asthma. J Allergy Clin Immunol
2005; 115: 233-42.
|
|
25.
|
Bisgaard H, Zielen S, Garcia-Garcia LM et al. Montelukast reduces asthma exacerbations in 2- to 5-year-old children with intermittent asthma.
Am J Respir Crit Care Med 2005; 171: 315-22.
|
|
26..
|
Anderson SD. How does exercise cause asthma attacks? Curr Opin Allergy Clin Immunol
2006; 6: 37-42.
|
|
27.
|
Hallstrand TS, Moody MW, Aitken ML et al. Airway immunopathology of asthma with exercise-induced bronchoconstriction.
J Allergy Clin Immunol 2005; 116: 586-93.
|
|
28.
|
Anderson SD. Single-dose agents in the prevention of exerciseinduced asthma: a descriptive review. Treat Respir Med 2004; 3: 365-79.
|
|
29.
|
Philip G, Villaran C, Pearlman DS et al. Protection against exercise-induced bronchoconstriction two hours after a single oral dose of montelukast.
J Asthma 2007; 44: 213-17.
|
|
30.
|
Melo RE, Sole D, Naspitz CK. Exercise-induced bronchoconstriction in children: montelukast attenuates the immediate-phase and latephase responses.
J Allergy Clin Immunol 2003; 111: 301-7.
|
|
31.
|
Kemp JP, Dockhorn RJ, Shapiro GG et al. Montelukast once daily inhibits exercise-induced bronchoconstriction in 6- to 14-year-old children with asthma.
J Pediatr 1998; 133: 424-8.
|
|
32
|
Kim JH, Lee SY, Kim HB et al. Prolonged effect of montelukast in asthmatic children with exercise-induced bronchoconstriction. Pediatr Pulmonol 2005; 39: 162-6.
|
|
33
|
Anderson SD, Caillaud C, Brannan JD. Beta2-agonists and exercise-induced asthma. Clin Rev Allergy Immunol 2006; 31: 163-80.
|
|
34
|
Wilson AM, O'Byrne PM, Parameswaran K. Leukotriene receptor antagonists for allergic rhinitis: a systematic review and meta-analysis. Am J Med 2004; 116: 338-44.
|
|
35.
|
Michele TM, Lu S, Malice M-P et al. Combination of montelukast and loratadine in seasonal allergic rhinitis: An analysis of three spring studies.
J Allergy Clin Immunol 2000; 104: S387 [Abstract].
|
|
36.
|
Michele TM et al. Combination of montelukast and loratadine improves quality of life in seasonal allergic rhinitis: An analysis of three spring studies.
Allergy 2000; 55 (Suppl 63): 42 [Abstract].
|
|
37.
|
Razi C, Bakirtas A, Harmanci K, Turktas I, Erbas D. Effect of montelukast on symptoms and exhaled nitric oxide levels in 7- to 14-year-old children with seasonal allergic rhinitis.
Ann Allergy Asthma Immunol 2006; 97: 767-74.
|
|
38.
|
Chen ST, Lu KH, Sun HL et al. Randomized placebo-controlled trial comparing montelukast and cetirizine for treating perennial allergic rhinitis in children aged 2-6 years.
Pediatr Allergy Immunol 2006;17: 49-54.
|
|
39.
|
Chang AB, Winter D, Acworth JP. Leukotriene receptor antagonist for prolonged non-specifi c cough in children.
Cochrane Database Syst Rev 2006; 2.
|
|
40.
|
van Adelsberg J, Moy J, Wei LX et al. Safety, tolerability, and exploratory effi cacy of montelukast in 6- to 24-month-old patients with asthma.
Curr Med Res Opin 2005; 21: 971-9.
|
|
41.
|
Straub DA, Moeller A, Minocchieri S et al. The effect of montelukast on lung function and exhaled nitric oxide in infants with early childhood asthma.
European Respir J 2005; 25: 289-94.
|
|
42.
|
Phipatanakul W, Nowak-Wegrzyn A, Eggleston PA et al. The effi cacy of montelukast in the treatment of cat allergen-induced asthma in children.
J Allergy Clin Immunol 2002; 109: 794-9.
|
|
43.
|
Phipatanakul W, Greene C, Downes SJ et al. Montelukast improves asthma control in asthmatic children maintained on inhaled corticosteroids.
Ann Allergy Asthma Immunol 2003; 91: 49-54.
|
|
44.
|
Peroni D, Bodini A, Miraglia Del Giudice M et al. Effect of budesonide and montelukast in asthmatic children exposed to relevant allergens.
Allergy 2005; 60: 206-10.
|
|
45.
|
Bisgaard H; Study Group on Montelukast and Respiratory Syncytial Virus. A randomized trial of montelukast in respiratory syncytial viruspostbronchiolitis.
Am J Respir Crit Care Med 2003; 167: 379-83.
|
